摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 2,4-dioxo-3-methyl-1,2,3,4-tetrahydroquinazoline-6-carboxylate | 118621-01-5

中文名称
——
中文别名
——
英文名称
methyl 2,4-dioxo-3-methyl-1,2,3,4-tetrahydroquinazoline-6-carboxylate
英文别名
methyl 3-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylate;methyl 3-methyl-2,4-dioxo-1H-quinazoline-6-carboxylate
methyl 2,4-dioxo-3-methyl-1,2,3,4-tetrahydroquinazoline-6-carboxylate化学式
CAS
118621-01-5
化学式
C11H10N2O4
mdl
——
分子量
234.211
InChiKey
YVNBLKWXSUNSRF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    75.7
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Studies on positive inotropic agents. V. Synthesis of 1-heteroaroylpiperazine derivatives.
    作者:HIDENORI OGAWA、SHIGEHARU TAMADA、TAKAFUMI FUJIOKA、SHUJI TERAMOTO、KAZUMI KONDO、SHUJI YAMASHITA、YOUICHI YABUUCHI、MICHIAKI TOMINAGA、KAZUYUKI NAKAGAWA
    DOI:10.1248/cpb.36.2253
    日期:——
    A series of 1-heteroaroylpiperazines (V-VII, XI) was synthesized and examined for positive inotropic activities on the canine heart. The key intermediates, heteroarenecarboxylic acids (III, X), were prepared by two different methods, and were condensed with substituted piperazines to give 1-heteroaroylpiperazines V-VII and XI. Among them, quinazoline derivatives (XI) were found to have potent positive inotropic activities.
    合成了一系列1-杂芳基哌嗪(V-VII, XI),并对其在犬心脏上的正性肌力活性进行了研究。关键中间体杂芳基羧酸(III, X)采用两种不同的方法制备,并与取代哌嗪缩合,得到1-杂芳基哌嗪V-VII和XI。其中,喹唑啉衍生物(XI)被发现具有强的正性肌力活性。
  • Substituted hydroxamic acids and uses thereof
    申请人:England Dylan B.
    公开号:US08765773B2
    公开(公告)日:2014-07-01
    This invention provides compounds of formula (I): wherein R1a, R1b, Ra, R2a, R2b, R1, and X have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    本发明提供了公式(I)的化合物:其中R1a,R1b,Ra,R2a,R2b,R1和X的值如规范中所述,可用作HDAC6的抑制剂。该发明还提供了包含本发明化合物的制药组合物和使用该组合物治疗增生性、炎症性、传染性、神经性或心血管疾病或障碍的方法。
  • OGAWA, HIDENORI;TAMADA, SHIGEHARU;FUJIOKA, TAKAFUMI;TERAMOTO, SHUJI;KONDO+, CHEM. AND PHARM. BULL., 36,(1988) N 6, 2253-2258
    作者:OGAWA, HIDENORI、TAMADA, SHIGEHARU、FUJIOKA, TAKAFUMI、TERAMOTO, SHUJI、KONDO+
    DOI:——
    日期:——
  • US8765773B2
    申请人:——
    公开号:US8765773B2
    公开(公告)日:2014-07-01
  • [EN] SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF<br/>[FR] ACIDES HYDROXAMIQUES SUBSTITUÉS ET LEURS UTILISATIONS
    申请人:MILLENNIUM PHARM INC
    公开号:WO2012054332A1
    公开(公告)日:2012-04-26
    This invention provides compounds of formula (I): wherein R1a, R1b, Ra, R2a, R2b, R1, and X have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
查看更多